2.45
+0.01(+0.41%)
Currency In USD
| Previous Close | 2.44 |
| Open | 2.46 |
| Day High | 2.56 |
| Day Low | 2.44 |
| 52-Week High | 5.64 |
| 52-Week Low | 2.09 |
| Volume | 1.17M |
| Average Volume | 1.89M |
| Market Cap | 162.99M |
| PE | -2.82 |
| EPS | -0.87 |
| Moving Average 50 Days | 3.42 |
| Moving Average 200 Days | 3.43 |
| Change | 0.01 |
If you invested $1000 in Cardiff Oncology, Inc. (CRDF) 10 years ago, it would be worth $5.61 as of August 18, 2025 at a share price of $2.45. Whereas If you bought $1000 worth of Cardiff Oncology, Inc. (CRDF) shares 5 years ago, it would be worth $432.1 as of August 18, 2025 at a share price of $2.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
GlobeNewswire Inc.
Jul 29, 2025 8:07 PM GMT
– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose arm vs. control arm – – Onvansert
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
GlobeNewswire Inc.
Jun 17, 2025 8:05 PM GMT
– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call on July 29 at
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
GlobeNewswire Inc.
Jun 02, 2025 8:05 PM GMT
– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of onvansertib in combination with paclitaxel, and ob